The rare condition causes some people to see sounds or written words as colours, or experience tastes, smells and shapes in linked combinations. Famous synaesthetes include composers Franz Liszt or Olivier Messiaens, and this condition has been linked to creativity and intelligence.
Now Austrian medical researchers have identified a gene variation which reduces the sense of pain, giving hope for future treatments of pain sufferers, according to new research published in the journal Cell today (12 November 2010). Around one in five people around the world suffer from acute or chronic pain, with all its financial costs and emotional burden. Studies of twins have shown that at least half of the differences in the way we are sensitive to pain is inherited.
Scientists at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences in Vienna, led by Josef Penninger and Greg Neely, together with Clifford Woolf of Harvard Medical School, Boston, developed a system in fruit flies to model pain perception. The system allowed them to screen nearly the entire set of the fly’s genes in search for those that affect the insect’s response to noxious heat. After identifying 600 pain genes the researchers closed in on one known as á2ä3 which is involved in calcium ion channels. Doctors already know that these tiny pores in the cell membrane are targeted by some existing analgesics, helping to relieve pain, so it seemed a promising candidate gene for further studies.
The next stage was to test whether the á2ä3 gene also affects the way people feel heat and pain. Doctors in the USA looked at four different single-letter variations in DNA, within or close to the á2ä3 gene in 189 healthy volunteers. They found that some of the gene variations led to reduced sensitivity to acute pain in a test which gives the volunteer a quick series of heat pulses. Further testing in 169 patients who had undergone surgery for back pain caused by damaged discs showed that patients with these same gene variations were much less likely to have persisting chronic pain.
The research team then looked directly into the brain of mice with mutant á2ä3 genes with MRI scanners and, in cooperation with the group of Andreas Hess in Erlangen, Germany, showed that this gene controls the way heat pain signals are processed in the brain. In the mutant mice the nerve signals arrive in the brain correctly at the thalamus, a first pain processing centre, but are not properly sent on to the higher processing centres in the cortex, which should alert the animals to the sensation of pain. Instead the researchers found that areas in the brain cortex for sight, smell and hearing were being activated by the pain signal. Thus, the team stumbled upon the first ever known gene that appears to control sensory cross-activation or synaesthesia - a neurological condition where a stimulus of one sense triggers perception of another sense.
“To find that our mice showed sensory cross-activation was the most stunning result of our study, it was something we never looked for”, says Josef Penninger. “Multiple forms of synaesthesia exist including pain stimuli that trigger colour. Synaesthesia might affect up to 4% of the population, shows genetic linkage, and has been associated with intelligence and creativity. Thus, á2ä3 mutant mice might provide the first ever animal model to enable us to study the phenomenon of sensory cross-activation. This might open up an entirely new field of biology.”
“Genes give us an amazing and powerful tool to begin to understand how pain is generated, and which functional pathways and specific proteins are involved”, says Dr Woolf. “Understanding the molecular basis of pain will lead to the development of new analgesics, the identification of risk factors for chronic pain and improved decision-making about the suitability of surgical treatment for different patients”.
The paper „A genome-wide Drosophila screen for heat nociception identifies á2ä3 as an evolutionary conserved pain gene” (Neely et al.) will be published in Cell on November 12, 2010.
The IMBA – Institute for Molecular Biotechnology of the Austrian Academy of Sciences opened in 2003. It combines fundamental and applied research in the field of biomedicine. Interdisciplinary research groups address functional genetic questions, particularly those related to the origin of disease. The ultimate goal is to implement acquired knowledge into the development of innovative applications for prevention, diagnosis and treatment of disease.Contact:
Dr. Heidemarie Hurtl | idw
‘Farming’ bacteria to boost growth in the oceans
24.10.2016 | Max-Planck-Institut für marine Mikrobiologie
Calcium Induces Chronic Lung Infections
24.10.2016 | Universität Basel
Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion
Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
24.10.2016 | Earth Sciences
24.10.2016 | Life Sciences
24.10.2016 | Physics and Astronomy